Fei Deng1, Jie Lei2, Xueqin Zhang3, Weiwei Huang4, Yongjun Li3, Dehua Wu5. 1. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515; Department of Oncology, The Second People's Hospital of Yichang, Three Gorges University, Yichang 443000, P. R. China. 2. Department of Pathology, The Second People's Hospital of Yichang, Three Gorges University, Yichang 443000, P. R. China. 3. Department of Oncology, The Second People's Hospital of Yichang, Three Gorges University, Yichang 443000, P. R. China. 4. Department of Emergency, The Second People's Hospital of Yichang, Three Gorges University, Yichang 443000, P. R. China. 5. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, P. R. China.
Abstract
OBJECTIVE: KIAA1199 has been identified as an oncogene in many cancers. Here, we collected 153 cases of nonsmall cell lung cancer (NSCLC) tissues to investigate the relationships between KIAA1199 protein and clinical factors. MATERIALS AND METHODS: Immunohistochemistry (IHC) staining was used to detect the expression of KIAA1199. Follow-up included blood analysis, chest X-ray, ultrasound examination, and computed tomography was carried out every 3 months for the first 2 years and at 6-month intervals thereafter during the follow-up period (3 years). Kaplan-Meier survival analysis and Cox analysis were applied to identify the relationship between KIAA1199 and NSCLC. RESULTS: IHC results showed that 76 (49.67%) specimens had strong expression of KIAA1199 protein, with poor differentiation (P = 0.003), higher positive lymph node metastasis (P = 0.037), and higher tumor node metastasis stage (P = 0.016). Using Kaplan-Meier survival analysis, it is found that patients with high KIAA1199 protein expression have poor overall survival (P = 0.004). Cox analysis suggested that the KIAA1199 protein was an independent prognostic marker for NSCLC patients (P = 0.040). CONCLUSION: Our findings revealed that KIAA1199 protein could be applied in predicting NSCLC patient's outcome.
OBJECTIVE:KIAA1199 has been identified as an oncogene in many cancers. Here, we collected 153 cases of nonsmall cell lung cancer (NSCLC) tissues to investigate the relationships between KIAA1199 protein and clinical factors. MATERIALS AND METHODS: Immunohistochemistry (IHC) staining was used to detect the expression of KIAA1199. Follow-up included blood analysis, chest X-ray, ultrasound examination, and computed tomography was carried out every 3 months for the first 2 years and at 6-month intervals thereafter during the follow-up period (3 years). Kaplan-Meier survival analysis and Cox analysis were applied to identify the relationship between KIAA1199 and NSCLC. RESULTS: IHC results showed that 76 (49.67%) specimens had strong expression of KIAA1199 protein, with poor differentiation (P = 0.003), higher positive lymph node metastasis (P = 0.037), and higher tumor node metastasis stage (P = 0.016). Using Kaplan-Meier survival analysis, it is found that patients with high KIAA1199 protein expression have poor overall survival (P = 0.004). Cox analysis suggested that the KIAA1199 protein was an independent prognostic marker for NSCLCpatients (P = 0.040). CONCLUSION: Our findings revealed that KIAA1199 protein could be applied in predicting NSCLCpatient's outcome.
Authors: Christina A Markunas; Dana B Hancock; Zongli Xu; Bryan C Quach; Fang Fang; Dale P Sandler; Eric O Johnson; Jack A Taylor Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2020-08-17 Impact factor: 3.358